Literature DB >> 9020723

Central nervous system imaging in Crouzon's syndrome.

T W Proudman1, B E Clark, M H Moore, A H Abbott, D J David.   

Abstract

Although the need to prevent the secondary effects of craniosynostosis on the central nervous system is fundamental to the practice of craniofacial surgery, the detailed structural anatomy of the central nervous system in the syndromal craniosynostoses has become the subject of recent interest. A clinical and radiographic review of a population of 59 patients with Crouzon's syndrome determined the frequency of central nervous system deformities. Twelve percent of patients had evidence of decreased mental function. Ventriculomegaly on computed tomographic scan was present in 51% and found to be of three grades: mild, moderate, and severe (hydrocephalus). This was nonprogressive in 7 of the 11 patients with follow-up computed tomographic scans. Ten patients underwent surgical release to increase intracranial space; however, 6 of these patients showed no progression in ventricular size. Nonventricular anomalies were found less frequently (14%). Central nervous system findings show fewer nonventricular anomalies than in Apert's syndrome patients, with a corresponding higher mental function. The principal anomaly of ventriculomegaly is not directly related to suture defect and may represent a primary brain abnormality. Recommendations are made for the assessment and management of patients with Crouzon's syndrome with reference to these areas.

Entities:  

Mesh:

Year:  1995        PMID: 9020723     DOI: 10.1097/00001665-199509000-00016

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  12 in total

1.  Guideline for Care of Patients With the Diagnoses of Craniosynostosis: Working Group on Craniosynostosis.

Authors:  Irene M J Mathijssen
Journal:  J Craniofac Surg       Date:  2015-09       Impact factor: 1.046

2.  Structural brain differences in school-age children with and without single-suture craniosynostosis.

Authors: 
Journal:  J Neurosurg Pediatr       Date:  2017-02-03       Impact factor: 2.375

3.  Morphology of the foramen magnum in syndromic and non-syndromic brachycephaly: letter to the editor.

Authors:  Guillaume Coll; Federico Di Rocco
Journal:  Childs Nerv Syst       Date:  2015-04-18       Impact factor: 1.475

4.  The growth of the foramen magnum in Crouzon syndrome.

Authors:  Guillaume Coll; Eric Arnaud; Laurent Selek; Francis Brunelle; Christian Sainte-Rose; Corinne Collet; Federico Di Rocco
Journal:  Childs Nerv Syst       Date:  2012-08-08       Impact factor: 1.475

Review 5.  Hydrocephalus in craniosynostosis: a review.

Authors:  H Collmann; N Sörensen; J Krauss
Journal:  Childs Nerv Syst       Date:  2005-04-27       Impact factor: 1.475

6.  Central nervous system phenotypes in craniosynostosis.

Authors:  Kristina Aldridge; Jeffrey L Marsh; Daniel Govier; Joan T Richtsmeier
Journal:  J Anat       Date:  2002-07       Impact factor: 2.610

7.  Growth hormone deficiency in a case of crouzon syndrome with hydrocephalus.

Authors:  Mei-Hong Wen; Hui-Pin Hsiao; Mei-Chyn Chao; Fuu-Jen Tsai
Journal:  Int J Pediatr Endocrinol       Date:  2010-05-30

Review 8.  Contemporary occurrence of hydrocephalus and Chiari I malformation in sagittal craniosynostosis. Case report and review of the literature.

Authors:  Francesco Giovanni Sgulò; Pietro Spennato; Ferdinando Aliberti; Giuliana Di Martino; Daniele Cascone; Giuseppe Cinalli
Journal:  Childs Nerv Syst       Date:  2016-07-22       Impact factor: 1.475

Review 9.  Brain malformation in syndromic craniosynostoses, a primary disorder of white matter: a review.

Authors:  Charles Raybaud; Concezio Di Rocco
Journal:  Childs Nerv Syst       Date:  2007-09-20       Impact factor: 1.475

10.  Tissue-specific responses to aberrant FGF signaling in complex head phenotypes.

Authors:  Neus Martínez-Abadías; Susan M Motch; Talia L Pankratz; Yingli Wang; Kristina Aldridge; Ethylin Wang Jabs; Joan T Richtsmeier
Journal:  Dev Dyn       Date:  2012-12-05       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.